SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

• Ages Any age
• Women only
• No healthy volunteers
• Child, Adult, Older adult

Trial locations and contacts

8 sites in 2 countries.

About this study

Official title: An Open, Multicenter Phase II Trial Evaluating the Antitumour Efficacy of Faslodex® (Fulvestrant) in Postmenopausal Women With Advanced Breast Cancer Failing Non-Steroidal or Steroidal Aromatase Inhibitors

Conditions

Breast Neoplasms

Being tested

Fulvestrant

Keywords

breast cancer, fulvestrant, Faslodex, hormonotherapy, aromatase inhibitor failure, Advanced breast cancer

Medical subject headings

Breast Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

• FulvestrantDrug

What is being measured

The primary outcome is the main question the study is designed to answer.

1. Clinical Benefit Rate

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1. First posted9 Jan 2006 (estimated)
2. Study startMar 2000

Resources

• Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
• Other trials for Breast NeoplasmsStudies of the same condition, open and under way.
• More trials run by AstraZenecaThe sponsor's other registered studies.
• What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.